Business Context and Reporting Period
This Form 8-K was filed by Illumina, Inc. on November 16, 2012. The report addresses a tender offer situation involving Complete Genomics, Inc. Illumina confirmed its status as "Party H" in the Schedule 14D-9 filed by Complete Genomics regarding a tender offer by Beta Acquisition Corporation, a subsidiary of BGI-Shenzhen.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for Illumina, Inc. The document focuses exclusively on the terms of a proposed acquisition.
Material Changes and Acquisition Proposal
Illumina confirmed it submitted proposals to acquire Complete Genomics. The most recent proposal, submitted on November 5, 2012, included the following material terms:
- Purchase Price: $3.30 per share in cash.
- Premium: Approximately 5% higher than the consideration offered by BGI.
- Financing: Funded entirely with cash-on-hand.
- Conditions: No condition for further due diligence.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of general business risks. The primary contingency disclosed is the ongoing competition with BGI-Shenzhen for the acquisition of Complete Genomics.
Investor Verification Checklist
- Verify the current status of the tender offer for Complete Genomics and whether Illumina's $3.30 per share proposal was accepted.
- Confirm Illumina's available cash-on-hand to ensure the proposed acquisition is fully fundable without external financing.
- Review subsequent filings to determine if the acquisition was completed or if the terms were revised.